<DOC>
	<DOCNO>NCT00099970</DOCNO>
	<brief_summary>This clinical trial conduct determine tumor response preliminary safety monoclonal antibody specifically bind cell surface receptor ( α5β1 integrin ) require establishment new blood vessel tumor growth , process know angiogenesis .</brief_summary>
	<brief_title>Volociximab Combination With DTIC Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Males female least 18 year age stage IV unresectable stage III nonocular melanoma may receive 0 2 prior regimen metastatic disease biological therapy immunotherapy ( e.g. , IL2 interferonalfa ) . Measurable disease accord Response Criteria Solid Tumors ( RECIST ) . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 1 . Estimated survival great equal 4 month . Negative pregnancy test ( woman childbearing potential ) . Pretreatment laboratory level meet specific criterion . Signed informed consent , include permission use protect health information . Prior treatment M200 a5b1 inhibitor murine chimeric monoclonal antibody . Prior treatment DTIC , temozolomide , chemotherapeutic regimen . Known sensitivity murine proteins chimeric antibody component product . Use investigational drug within 4 week prior screen 5 halflives prior investigational drug ( whichever longer ) . Systemic biologic , immunotherapy , and/or radiation therapy within 4 week first dose M200 . Documented central nervous system ( CNS ) tumor CNS metastasis . History thromboembolic event bleed disorder within past year . Medical condition may exacerbate bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Metastatic melanoma</keyword>
</DOC>